DOCSLIB.ORG

Impact of Duffy Antigen Receptor for Chemokines (DARC)-Null Linked Neutropenia on Neutrophil and Natural Killer Cell Function in HIV-1 Infection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impact of Duffy Antigen Receptor for Chemokines (DARC)-Null Linked Neutropenia on Neutrophil and Natural Killer Cell Function in HIV-1 Infection Impact of Duffy Antigen Receptor for Chemokines (DARC)-null linked Neutropenia on Neutrophil and Natural Killer cell Function in HIV-1 Infection Kewreshini K. Naidoo Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in Immunology at the Nelson R. Mandela School of Medicine, College of Health Sciences University of KwaZulu-Natal, Durban. 2018 PREFACE This project represents original work done by the author and where others have made contributions it has been acknowledged in the text. This work has not been submitted in any form for any degree or diploma at another tertiary institution. The experimental work described in this thesis was performed in the HIV Pathogenesis Programme Laboratory at the Doris Duke Medical Research Institute at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal in Durban, South Africa. The work was supervised by Dr Christina F. Thobakgale-Tshabalala and Professor Thumbi Ndung’u. Kewreshini K. Naidoo Signed: Date: 04 December 2018 Christina F. Thobakgale-Tshabalala Signed: Date: 04 December 2018 As the candidate’s supervisor I agree to the submission of this thesis. Christina F. Thobakgale-Tshabalala Signed: Date: 04 December 2018 i DECLARATION I, Kewreshini K. Naidoo, declare that (i) The research reported in this thesis, except where otherwise indicated, is my original work. (ii) This thesis has not been submitted for any degree or examination at any other university. (iii) This thesis does not contain other person’s data, pictures, graphs or other information, unless specifically acknowledged as being sourced from other persons. (iv) This thesis does not contain other persons’ writing, unless specifically acknowledged as being sourced from other researchers. Where other written sources have been quoted, then: (a) their words have been re-written but the general information attributed to them has been referenced; (b) where their exact words have been used, their writing has been placed inside quotation marks, and referenced. (v) Where I have reproduced a publication of which I am author, co-author or editor, I have indicated in detail which part of the publication was actually written by myself and have fully referenced such publications. (vi) This thesis does not contain text, graphics or tables copied and pasted from the Internet, unless specifically acknowledged, and the source being detailed in the thesis and in the References section. Signed: Date: 04 December 2018 ii PUBLICATIONS AND PRESENTATIONS Peer-reviewed Publications Thobakgale, C., Naidoo, K., Mckinnon, L. R., Werner, L., Samsunder, N., Karim, S. A., Ndung'u, T., Altfeld, M. & Naidoo, K. 2017. Interleukin 1-Beta (IL-1beta) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV- Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 74, 213-220. Zulu, M. Z., Naidoo, K. K., Mncube, Z., Jaggernath, M., Goulder, P. J. R., Ndung'u, T., Altfeld, M. & Thobakgale, C. F. 2017. Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56(-)CD16(+) Natural Killer Cell Subset Is Associated with Natural Killer Cell Dysfunction in Chronic HIV-1 Clade C Infection. AIDS Res Hum Retroviruses, 33, 1205-1213 (shared first author). Naidoo, K.K., Ngubane, A., Gaza, P., Moodley, A., Ndung'u, T., Thobakgale, C.F. Neutrophil Effector Functions are not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-null Black South Africans. Frontiers in Immunology (in press). Presentations Naidoo, K.K., Mbhele, N., Ngubane, A., Dong, K.L., Ndung’u, T. and Thobakgale-Tshabalala, C.F. NK Cell Responses in a DARC-null Zulu/Xhosa African HIV-1 Infected Population. Keystone Symposia on Molecular and Cellular Biology: HIV Vaccines, 20-24 March 2016, Olympic Valley, California, USA. Abstract X8 3047 (poster presentation). Naidoo, K.K., Mbhele, N., Rashid, T., Ngubane, A., Dong, K.L., Ndung’u, T. and Thobakgale- Tshabalala, C.F. NK Cell Responses in a DARC-null Zulu/Xhosa African HIV-1 Infected Population. University of KwaZulu-Natal College of Health Sciences Research Symposium, 8-9 September 2016, Durban, KwaZulu-Natal, South Africa (oral presentation). Naidoo, K.K., Ngubane, A., Gaza, P., Moodley, A., Ndung'u, T., Thobakgale, C.F. Neutrophil Effector Functions are not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-null Black South Africans. European Society for Clinical Investigation (ESCI) Congress, 22-24 May 2019, Coimbra, Portugal (poster presentation). iii ACKNOWLEDGEMENTS I would like to thank: Dr Christina Thobakgale-Tshabalala and Professor Thumbi Ndung’u for their supervision, encouragement and mentorship throughout this study. Professor Arturo Zychlinsky for hosting my time at the Max Planck Institute for Infection Biology. Christian Goosmann and Falko Apel for training of neutrophil isolation and functional assays. Nokuzola Mbhele and Tabassum Rashid for their exceptional technical assistance in the laboratory. The participants of the FRESH and HPP Acute Infection Cohorts and our dedicated clinic staff. The South African Medical Research Council, the National Research Foundation and Sullivan Funding for financial support of this study. iv ABSTRACT Sub-Saharan Africa carries a disproportionate burden of the HIV-1 epidemic. The Duffy Antigen Receptor for Chemokines (DARC)-null polymorphism is a predictor of ethnic neutropenia which commonly occurs in persons of African ethnicity and is thought to account for up to 11% of HIV-1 infections on the African continent. Neutrophils are recognised for their killing mechanisms and have been noted for their regulatory mechanisms in recent years. For example, a role for neutrophils in natural killer (NK) cell priming in the periphery has been suggested, and neutrophil deficiency has been implicated in contributing to NK cell immaturity and dysfunction. While the DARC-null genotype is well associated with lower absolute neutrophil counts (ANCs), studies that assess the effects of the polymorphism on neutrophil functionality are lacking and the impact of DARC-null linked neutropenia on HIV disease progression is debatable. Furthermore, the influence of DARC-null neutropenia on the NK cell compartment is unknown. In this cross sectional pilot study, we assessed the impact of the DARC-null trait on neutrophil effector functions and also characterised NK cell profiles in Zulu/Xhosa African individuals from a high incidence HIV setting in Durban, South Africa. We hypothesised that in the context of the DARC-null genotype and lower ANCs in our cohort participants, neutrophils would have impaired functionality and would be unable to efficiently prime NK cells; thus affecting NK cell maturation and function, and altering NK cell homeostatic activities such as survival and proliferation. We further hypothesised that the impaired cellular responses in DARC-null individuals would be more prominent in HIV-1 infected individuals compared to HIV negative individuals. Neutrophil killing mechanisms were measured in HIV-1 chronically infected (n=22) individuals and HIV negative (uninfected) controls (n=20). For assessment of key neutrophil effector functions, isolated neutrophils were evaluated for Fc receptor-mediated phagocytosis following uptake of IgG opsonised beads using flow cytometry; reactive oxygen species (ROS) emission was measured by chemi-luminesce after activation of neutrophils with phorbol 12- myristate 13-acetate (PMA). Activated neutrophils were also visualised by fluorescent microscopy for neutrophil extracellular trap (NET) quantification. Assessment of the NK cell compartment in chronically HIV-1 infected (n=18) and uninfected (n=20) individuals using multi-parametric flow cytometry determined NK cell subsets, maturation profiles, cytokine production and degranulation. Annexin V and propidium iodide assays were used to determine NK cell survival, whilst CFSE staining was used to examine cytokine-activated NK cell v proliferation. Study subjects were genotyped for the DARC trait using TaqMan allelic discrimination assays and ANCs were measured by full blood count. Our findings confirmed a high prevalence of the DARC-null allele in the African population and the polymorphism was significantly associated with lower ANCs. Neutrophil functional analysis detected rapid and higher phagocytic activity in the absence of DARC at 10 minutes (p=0.05 and p=0.009) and 60 minutes (p=0.05 and p=0.07) in HIV negative and HIV-1 infected subjects respectively. ROS and NET production in neutrophils were mostly unaffected by DARC negativity irrespective of HIV status. The only exception to this was a reduction in NET production in neutrophils from DARC-null HIV infected subjects (p=0.04) following prolonged in vitro stimulation. In the NK cell compartment, individuals showed similar NK cell counts irrespective of HIV status. In HIV negative individuals, a marked reduction of total NK cell counts was noted in the absence of DARC (p=0.006) and this correlated with lower ANCs (p=0.002) and a weak trend towards higher CD56 bright subset proportions was noted in DARC-null individuals (p=0.08). HIV negative DARC-null subjects also displayed a less mature NK cell phenotype with higher proportions of hypo-responsive KIR-NKG2A- NK cells (p=0.06) and lower frequencies of terminally differentiated CD57 (p=0.02) expressing NK cells. However, this immature phenotype did not translate to differences in expression of NK cell activation markers CD69 or HLA-DR and exhaustion marker PD-1 by DARC state. Furthermore,
Load more

Recommended publications
  • Immuno 2014 No. 1
    Journal of Blood Group Serology and Molecular Genetics VOLUME 30, N UMBER 1, 2014 Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 30, Number 1, 2014 CONTENTS R EPORT 1 Indirect antiglobulin test-crossmatch using low-ionic-strength saline–albumin enhancement medium and reduced incubation time: effectiveness in the detection of most clinically significant antibodies and impact on blood utilization C.L. Dinardo, S.L. Bonifácio, and A. Mendrone, Jr. R EV I EW 6 Raph blood group system M. Hayes R EPORT 11 I-int phenotype among three individuals of a Parsi community from Mumbai, India S.R. Joshi C A SE R EPORT 14 Evans syndrome in a pediatric liver transplant recipient with an autoantibody with apparent specificity for the KEL4 (Kpb) antigen S.A. Koepsell, K. Burright-Hittner, and J.D. Landmark R EV I EW 18 JMH blood group system: a review S.T. Johnson R EPORT 24 Demonstration of IgG subclass (IgG1 and IgG3) in patients with positive direct antiglobulin tests A. Singh, A. Solanki, and R. Chaudhary I N M EMOR ia M 28 George Garratty, 1935–2014 Patricia A. Arndt and Regina M. Leger 30 A NNOUNCEMENTS 34 A DVERT I SEMENTS 39 I NSTRUCT I ONS FOR A UTHORS E D I TOR - I N -C H I EF E D I TOR ia L B OA RD Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Paul M. Ness, MD Pomona, California Baltimore, Maryland M A N AG I NG E D I TOR James P.
    [Show full text]
  • Introduction to the Rh Blood Group.Pdf
    Introduction to the Rhesus Blood Group Justin R. Rhees, M.S., MLS(ASCP)CM, SBBCM University of Utah Department of Pathology Medical Laboratory Science Program Objectives 1. Describe the major Rhesus (Rh) blood group antigens in terms of biochemical structure and inheritance. 2. Describe the characteristics of Rh antibodies. 3. Translate the five major Rh antigens, genotypes, and haplotypes from Fisher-Race to Wiener nomenclature. 4. State the purpose of Fisher-Race, Wiener, Rosenfield, and ISBT nomenclatures. Background . How did this blood group get its name? . 1937 Mrs. Seno; Bellevue hospital . Unknown antibody, unrelated to ABO . Philip Levine tested her serum against 54 ABO-compatible blood samples: only 13 were compatible. Rhesus (Rh) blood group 1930s several cases of Hemolytic of the Fetus and Newborn (HDFN) published. Hemolytic transfusion reactions (HTR) were observed in ABO- compatible transfusions. In search of more blood groups, Landsteiner and Wiener immunized rabbits with the Rhesus macaque blood of the Rhesus monkeys. Rhesus (Rh) blood group 1940 Landsteiner and Wiener reported an antibody that reacted with about 85% of human red cell samples. It was supposed that anti-Rh was the specificity causing the “intragroup” incompatibilities observed. 1941 Levine found in over 90% of erythroblastosis fetalis cases, the mother was Rh-negative and the father was Rh-positive. Rhesus macaque Rhesus (Rh) blood group Human anti-Rh and animal anti- Rh are not the same. However, “Rh” was embedded into blood group antigen terminology. The
    [Show full text]
  • 3407 M16141436 19 3.Pdf
    Immunohematology JOURNAL OF BLOOD GROUP SEROLOGY AND EDUCATION V OLUME 19, NUMBER 3, 2003 Immunohematology JOURNAL OF BLOOD GROUP SEROLOGY AND EDUCATION V OLUME 19, NUMBER 3, 2003 CONTENTS 73 DNA analysis for donor screening of Dombrock blood group antigens J.R. STORRY, C.M.WESTHOFF,D.CHARLES-PIERRE,M.RIOS,K.HUE-ROYE,S.VEGE,S.NANCE, AND M.E. REID 77 Studies on the Dombrock blood group system in non-human primates C. MOGOS,A.SCHAWALDER,G.R. HALVERSON, AND M.E. REID 83 Murine monoclonal antibodies can be used to type RBCs with a positive DAT G.R. HALVERSON,P.HOWARD,H.MALYSKA,E.TOSSAS, AND M.E. REID 86 Rh antigen and phenotype frequencies and probable genotypes for the four main ethnic groups in Port Harcourt, Nigeria Z.A. JEREMIAH AND F.I. BUSERI 89 Antibodies detected in samples from 21,730 pregnant women S. JOVANOVIC-SRZENTIC,M.DJOKIC,N.TIJANIC,R.DJORDJEVIC,N.RIZVAN,D.PLECAS, AND D. FILIMONOVIC 93 BOOK REVIEWS S. GERALD SANDLER,MD THERESA NESTER,MD 95 COMMUNICATIONS Letter to the Editors Letter From the Editors Irregular RBC antibodies in the Ortho Dedication sera of Brazilian pregnant women 97 IN MEMORIAM BERTIL CEDEGREN,MD 98 99 ANNOUNCEMENTS ADVERTISEMENTS 103 INSTRUCTIONS FOR AUTHORS EDITOR-IN-CHIEF MANAGING EDITOR Delores Mallory, MT(ASCP)SBB Mary H. McGinniss,AB, (ASCP)SBB Rockville, Maryland Bethesda, Maryland TECHNICAL EDITOR SENIOR MEDICAL EDITOR Christine Lomas-Francis, MSc Scott Murphy, MD New York, New York Philadelphia, Pennsylvania ASSOCIATE MEDICAL EDITORS S. Gerald Sandler, MD Geralyn Meny, MD Ralph Vassallo, MD Washington, District of Columbia Philadelphia, Pennsylvania Philadelphia, Pennsylvania EDITORIAL BOARD Patricia Arndt, MT(ASCP)SBB W.
    [Show full text]
  • Comprehensive Red Blood Cell and Platelet Antigen Prediction from Whole Genome Sequencing: Proof of Principle
    BLOOD GROUP GENOMICS Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle William J. Lane,1,2 Connie M. Westhoff,3 Jon Michael Uy,1 Maria Aguad,1 Robin Smeland-Wagman,1 Richard M. Kaufman,1 Heidi L. Rehm,1,2,4,5 Robert C. Green,2,5,6 and Leslie E. Silberstein7 for the MedSeq Project* rediction of red blood cell (RBC) and platelet BACKGROUND: There are 346 serologically defined (PLT) antigens using DNA assays has the poten- red blood cell (RBC) antigens and 33 serologically tial to augment or replace traditional serologic defined platelet (PLT) antigens, most of which have antigen typing in many situations. DNA-based known genetic changes in 45 RBC or six PLT genes that P typing methods are more easily automated, amenable to correlate with antigen expression. Polymorphic sites multiplexing, and do not require expensive and some- associated with antigen expression in the primary times difficult to obtain serologic immunoglobulin literature and reference databases are annotated according to nucleotide positions in cDNA. This makes antigen prediction from next-generation sequencing data ABBREVIATIONS: CDS 5 coding DNA sequence; NGS 5 challenging, since it uses genomic coordinates. next-generation sequencing; SNP(s) 5 single-nucleotide STUDY DESIGN AND METHODS: The conventional polymorphism(s); WGS 5 whole genome sequencing. cDNA reference sequences for all known RBC and PLT From the 1Department of Pathology, the 6Division of Genetics, genes that correlate with antigen expression were Department of Medicine, and the 7Division of Transfusion aligned to the human reference genome. The alignments Medicine, Department of Pathology, Brigham and Women’s allowed conversion of conventional cDNA nucleotide Hospital; and 2Harvard Medical School, Boston, Massachusetts; positions to the corresponding genomic coordinates.
    [Show full text]
  • Red Blood Cell Antigen Genotyping
    Red Blood Cell Antigen Genotyping Testing is useful in determining allelic variants predicting red blood cell (RBC) antigen phenotypes for patients with recent history of transfusion or with conflicting serological antibody results due to partial, variant, or weak expression antigens. Also Tests to Consider useful as an aid in management of hemolytic disease of the fetus and newborn (HDFN). Typical Testing Strategy Disease Overview Phenotype Testing Evaluates specific RBC antigen presence by serology Prevalence and/or Incidence Results can aid in selecting antigen negative RBC units Erythrocyte alloimmunization occurs in up to 58% of sickle cell patients, up to 35% in other transfusion-dependent patients, and in approximately 0.8% of all pregnant Antigen Testing, RBC Phenotype women. Extended 0013020 Method: Hemagglutination Serological testing includes K, Fya, Fyb, Jka, Symptoms Jkb, S, s (k, cellano, testing performed if indicated) to assess maternal or paternal RBC Transfusion reactions or HDFN can occur due to alloimmunization: phenotype status. Antigen Testing, Rh Phenotype 0013019 Intravascular hemolysis: hemoglobinuria, jaundice, shock Extravascular hemolysis: fever and chills Method: Hemagglutination HDFN: fetal hemolytic anemia, hepatosplenomegaly, jaundice, erythroblastosis, Antigen testing for D, C, E, c, and e to assess neurological damage, hydrops fetalis maternal, paternal, or newborn Rh phenotype status Clinical presentation is variable and dependent upon the specific antibody and recipient factors Genotype Testing May help
    [Show full text]
  • Copyrighted Material
    P1: SFK/UKS P2: SFK/UKS QC: SFK/UKS T1: SFK Color: 1C ind BLBK321-Paidas September 7, 2010 15:9 Trim: 244mm X 172mm Index Note: Italicized f and t refer to figures and tables, respectably. Abciximab, 207 anti-A, 29 ABO blood group, 28–9 anti-B, 29 ABO hemolytic disease, 29 anti-c, 28 acetaminophen, 45 anticoagulant therapy, 111–43 acidosis, 197 antiplatelet agents, 141 acquired thrombophilia, 68–74. See also low molecular weight heparin, 127–30, inherited thrombophilia 140–41 diagnosis of, 68, 72t for mechanical heart valve incidence of, 68 thromboprophylaxis, 138–43 obstetrical complications, 73 unfractionated heparin, 127, 140–41 pathogenecity, 71 for venous thromboembolism, 111–18 pathophysiology of, 71 for venous thromboembolism in pregnancy, activated partial thromboplastin time (aPTT), 118–36 127, 173 vitamin K antagonists, 139–40 activated protein C (APC), 6, 74–9, 191 anti-D immunoglobulin, 33 activated recombinant factor VII (rFVIIa), 165 antenatal, 33 activation markers, 7 dose regime, 35 acute fatty liver of pregnancy (AFLP), 187 indications for RhD-negative mothers, 35 acute leukemia, 20 antifibrinolytic drugs, 202 ADAMST13 deficiency, 44 anti-Kell, 28 adenosine diphosphate (ADP), 60, 61–2 f antiphospholipid antibody syndrome (APAS), adherent placenta, 169–70 68–74 alpha-delta storage pool deficiency, 165 clinical consequences, 72–3 Alport syndrome, 60 diagnosis of, 68, 72t amegakaryocytic thrombocytopenia, 60 incidence of, 68 amniotic fluid embolism (AFE), 184–5 obstetrical complications, 73 anaphylaxis, 211 pathogenicity, 71 anemia,
    [Show full text]
  • Blood Group Antigens: Principles and Practice
    Blood Group Antigens: principles and practice Peyman Eshghi Prof. of Pediatric Hematology & Oncology 3-95 References 1. NATHAN AND OSKI’S HEMATOLOGY AND ONCOLOGY OF INFANCY AND CHILDHOOD, 8 th ed.,2015 2. Christopher D. Hillyer,et al.,Handbook of PEDIATRIC TRANSFUSION MEDICINE,2004 3. Rossi’sPrinciplesofTransfusionMedicine,5th ed.,2015 • More than 250 Ags • Erythrocyte antigens are polymorphic inherited structural characteristics located on proteins, glycoproteins, or glycolipids on the outside surface of the RBC membrane. • Erythrocyte antigens are clinically important in the immune destruction of RBCs in allogeneic blood transfusions, maternal-fetal blood group incompatibility, autoimmune hemolytic anemia, and organ transplantation Carbohydrate blood groups •ABO •LEWIS •P •Hh • The fucosyltransferase (and thus the H antigen) is present in all persons except those with the rare Bombay (Oh) phenotype • The genes for the A and B blood group antigens are codominant • Antigens A&B are not fully developed until 2 to 4 years of age:ABO hemolytic disease of the newborn (HDN) is usually a mild disease • Isohemagglutinins from group A and B individuals are predominantly immunoglobulin M (IgM) that do not usually cross the placenta and cause HDN. • However, as group O serum contains IgG isohemagglutins, ABO HDN is most frequently seen in non–group O infants of group O mothers. Molecular basis of ABH • Three genes control the expression of the ABO antigens: • ABO, Hh, and Se. • The H gene attaches L-fucose to the RBC membrane-anchored polypeptide • On red cells, platelets ,and endothelium ,ABH is primarily expressed on type 2 chain or lactosamine based structures. • The secretor gene (Se) controls the individual’s ability to secrete soluble • Genitourinary and gastrointestinal tissues, are rich in type1 chain ABH antigens : depends on secretor gen FUT2 • The classic Bombay phenotype: is an H-deficient nonsecretor(hh,se/se), with an absence of both type1 and type2 chain ABH antigens.
    [Show full text]
  • Obstetrics and Gynecology, Howard C
    Red Cell Alloimmunization Chapter 34 KeNNeth J. MOISe Jr Nomenclature 770 Indications 774 Hemolytic Disease of the Fetus Historic Perspectives 770 Diagnostic Methods 776 and Newborn Due to Non-RhD Incidence 771 Clinical Management 778 Antibodies 781 Pathophysiology 771 First Affected Pregnancy 778 Rhc 781 Rhesus Alloimmunization and Fetal/ Previously Affected Fetus or Infant 778 RhC, RhE, and Rhe 782 Neonatal Hemolytic Disease of the Intrauterine Transfusion 778 Duffy 782 Newborn 772 Technique 778 Kidd 782 Genetics 772 Complications and Outcome 780 Kell 782 Prevention of RhD Hemolytic Disease Neonatal Transfusions 780 in the Fetus and Newborn 773 Neurologic Outcome 780 History 773 Other Treatment Modalities 780 Preparations 773 Future Therapeutic Options 781 KEY ABBREVIATIONS these antibodies across the placenta during pregnancy results in fetal anemia, hyperbilirubinemia, and ultimately hydrops American Association of Blood Banks AABB fetalis. Before the advent of obstetric ultrasound, the perinatal American College of Obstetricians and ACOG effects of maternal red cell alloimmunization could be recog- Gynecologists nized only after birth in the affected neonate. Thus the neonatal Cytomegalovirus CMV consequences of maternal red cell alloimmunization came to be Circulating cell-free fetal DNA ccffDNA known as hemolytic disease of the newborn (HDN). Because the Deoxyribonucleic acid DNA peripheral blood smear of these infants demonstrated a large Diphosphatidylglycerol DPG percentage of circulating immature red cells known as erythro­ Fetal blood sampling FBS blasts, the newborn entity was also known as erythroblastosis Fetomaternal hemorrhage FMH fetalis. Today, ultrasound and fetal blood sampling (FBS) make Grams per deciliter g/dL the detection of the severely anemic fetus a reality.
    [Show full text]
  • Sõnastik, Nimeregister, Kirjandus
    SÕNASTIK A (ingl. adenine, A), adeniin. Puriinalus adenosiinnukleotiidis, DNA-s ja RNA-s. Vt. C, G ja T. Aafrikast-välja-hüpotees (ingl. Out-of-Af ica hypothesis). Arvatakse, et nüüdisinimene on tekkinud Aafrikas ja rännanud sealt teistele kontinentidele. aberrantne Ds-element (ingl. Abberant Ds element). Maisi transposoon Ds, mille pöördkordusjärjestuste vahel asub võõr-DNA. abifaag (ingl. Helper phage). Normaalne faag, mis täiendab defektset faagi, võimaldades selle paljunemist. abiplasmiid (ingl. Helper plasmid). Konjugatiivne plasmiid, mis täiendab defektse mit ekonjugatiivse plasmiidi tra-geenide toimet ja võimaldab selle ülekannet. ABI Solid-sekveneerimistehnoloogia (ingl. Sequencing by oligonucleotide ligation and detection). Uue põlvkonna sekveneerimistehnoloogia, mis põhineb järjestusespetsiifilisel oligonukleotiidide ühendamisel ligaasiga ning andmete arvutitöötlusel. abi-T-rakk (ingl. Helper T cell). T-rakud, mis reageerides makrofaagide poolt eks- poneeritavale antigeenile, stimuleerivad B- ja T-lümfotsüüte, et neist areneksid vastavalt antikehasid moodustavad plasmarakud ja tapja-T-rakud. AB0-veregrupid (ingl. AB0 blood groups). Kõige tähtsamad veretüübid inimese vere- ülekandel. Selles süsteemis on põhilised A-, B-, AB- ja 0-grupp, mis on määratud ühe geeni kolme alleeliga. abortiivne transduktsioon (ingl. Abortive transduction). Kui transduktsioonil ülekandunud DNA ei läbi bakteri DNA-ga homoloogset rekombinatsiooni, on rakk osaliselt diploidne. Sissetunginud DNA ei ole integreerunud kromosoomi ega replitseeru. abortiivne
    [Show full text]
  • SPECIFICATION SPN214/4 the Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion Copy Numb
    SPECIFICATION SPN214/4 The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion This Specification replaces Copy Number SPN214/3 Effective 03/05/17 Summary of Significant Changes Change of author to Nicole Thornton from Geoff Daniels (retired). Update to blood group systems (new systems added) Update to some rare antibodies due to availability of new data Change of regional coordinators and associated contact information Removal of unnecessary information to improve clarity Purpose This document outlines current knowledge on the clinical significance of blood group alloantibodies. Its prime purpose is to enable clinical decisions to be made regarding the management and blood transfusion support of patients with blood group antibodies that are not commonly encountered and for which antigen-negative blood is not available in the routine stock. The overall aim is to ensure that a uniform RCI Clinical Policy for the supply of blood for transfusion is implemented throughout the NHSBT. Definitions BSH British Committee for Standards in IAT Indirect Antiglobulin Test Haematology IBGRL International Blood Group DHTR Delayed Haemolytic Transfusion Reference Laboratory Reaction IRDP International Rare Donor Panel HDFN Haemolytic Disease of the Fetus NHSBT NHS Blood and Transplant and Newborn NFBB National Frozen Blood Bank HTR Haemolytic Transfusion Reaction RCI Red Cell Immunohaematology Applicable Documents ESD121 Guidelines for pre-transfusion INF1302: HGP project – targets, phenotype compatibility procedures
    [Show full text]
  • En Japan Prize News 39 01
    Medical Genomics and Genetics Leading the Human Genome Project Dr. McKusick also worked assiduously toward the founda- tion of the Human Genome Organization (HUGO), a develop- ment of the aforementioned Human Genome Mapping Work- shop, in order to bring together researchers on the Human Achievement Establishment of medical genetics and contributions to its development Genome Project to exchange information and to coordinate operations. Dr. McKusick himself served as the first Dr. Victor A. McKusick (U.S.A.) president of the organization. From the production of the University Professor of Medical Genetics, the McKusick- Nathans Institute of very first genetic mapping prototypes through to today’s Genetic Medicine at the Johns Hopkins University genomic map that is able to determine the entire human genome sequence, Dr. McKusick has been an instrumental figure, constantly playing a leading role in international genetic research. OUTLINE: Dr. McKusick is a man of remarkable foresight. As long as With the completion of the human genome project, we have in the category of “Medical Genomics and Genetic”, has spent over half a century ago, he strongly advocated giving full come to understand almost all of the genetic information over half a century compiling related knowledge, and advocat- recognition to the critical roles played by genes, and this has contained in DNA, which is encoded in a series of letters. ing the importance of the formulation of a genomic map for resulted in the compilation of a vast amount of genetic data However, we are still some way from fully identifying those genetic disorders. Today, researchers and clinicians around that, given the technological innovations in recent years, parts which are related to the treatment of diseases.
    [Show full text]
  • Blood Group Genetics
    Blood Group Genetics Department of Medical Genetics Medical University of Warsaw © Zakład Genetyki Medycznej 2013 Classical genetics Classical genetics laws: • Mendel's First Law – Law of Segregation • Mendel's Second Law – Law of Independent Assortment • Co-dominance – phenotypic expression of gene’s alleles is simultaneous and independent • Epistasis – phenomenon in which one gene influences the phenotypic expression of another gene, while not being its allele Blood Group Systems Blood Group – antigenic Group system – consists of one or more determinants on the antigens controlled at a single gene locus, or by two or more very closely surface of erythrocytes linked homologous genes distinguished by the Collection – consist of serologically, immune system in biochemically, or genetically related individuals without a antigens, which do not fit the criteria particular antigen required for system status (200 series) (alloantibodies) 901 Series – (or ’public’) contains antigens with an incidence of greater than 90% and which cannot be included in a system or collectioni 700 Series – (or ’private’) contains • 285 antigens antigens with an incidence of less than 1% and which cannot be included in a • 33 group systems system or collection Red blood cells group systems Nr Nazwa Symbol Gen Chromosom Nr Nazwa Symbol Gen Chromosom 001 ABO ABO ABO 9q34.2 018 H H FUT1 19q13.33 GYPA, GYPB, 002 MNS MNS GYPE 4q31.21 019 Kx XK XK Xp21.1 003 P1PK P1PK A4GALT 22q13.2 020 Gerbich GE GYPC 2q14.3 004 Rh RH RHD, RHCE 1p36.11 021 Cromer CROM CD55 1q32.2 005
    [Show full text]